Eton Pharmaceuticals, Inc.
Small-molecule pharmaceutical therapies for rare and underserved diseases
- Sector
- Biotech
- Headquarters
- DEER PARK, IL
- Founded
- 2017
- Latest Form D
- $7.5M, Apr 2020
- Total capital
- $27.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $27.6M
- 2 Form D · last Apr 2020
- 79 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 8 pending · first 2024
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$7.5M
- Private capital raisedForm D · SEC · 1st filing$20.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew BollDirectorNamed in SEC Form D filings
- Charles CasamentoDirectorNamed in SEC Form D filings
- Mark L BaumDirectorNamed in SEC Form D filings
- Norbert G RiedelDirectorNamed in SEC Form D filings
- Paul V MaierDirectorNamed in SEC Form D filings
- Sean BrynjelsenExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
- William Wilson TroutmanExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 11- PendingHydrocortisone Oral Liquid FormulationsUSPTOApplication 19307449
- GrantedHydrocortisone Oral Liquid FormulationsUSPTOUS 12,419,831
- GrantedHydrocortisone Oral Liquid FormulationsUSPTOUS 12,133,914
Show all 11 patent records
- Hydrocortisone Oral Liquid FormulationsJun 18, 2026 · Application 19307449Pending
- Hydrocortisone Oral Liquid FormulationsSep 23, 2025 · US 12,419,831Granted
- Hydrocortisone Oral Liquid FormulationsNov 5, 2024 · US 12,133,914Granted
- Hydrocortisone Oral Liquid FormulationsJun 6, 2024 · Application 18443875Pending
- Hydrocortisone Oral Liquid FormulationsFeb 20, 2024 · US 11,904,046Granted
- Ready-to-use Oxytocin Formulation And Uses ThereofDec 26, 2019 · Application 16013665Pending
- Adrenocorticotropic Hormone-based Pharmaceutical Formulations And Methods For Fabricating And Using ThereofJun 21, 2018 · Application 15621653Pending
- Hydrocortisone Oral Liquid FormulationsApplication PCTUS2023079494Pending
- Hydrocortisone Oral Liquid FormulationsApplication 63425172Pending
- Adrenocorticotropic Hormone-based Pharmaceutical Formulations And Methods For Fabricating And Using ThereofApplication PCTUS2017037240Pending
- Adrenocorticotropic Hormone-based Pharmaceutical Formulations And Methods For Fabricating And Using ThereofApplication 62436082Pending
Related companies, and why
- VIOME LIFE SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- IMMUDX, LLCSimilar federal contract value in Biotech · null in contracts
- Quince TherapeuticsSimilar federal contract value in Biotech · null in contracts
- CLARAMETYX BIOSCIENCES, INCSimilar federal contract value in Biotech · null in contracts
- KALA BIO, Inc.Similar federal contract value in Biotech · null in contracts
- Provenance Group, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .